Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)

समान संसाधन

• Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
  द्वारा: Blombery, Piers, और अन्य
  प्रकाशित: (2020)
• Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia
  द्वारा: Al-Sawaf, Othman, और अन्य
  प्रकाशित: (2019)
• Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
  द्वारा: Tausch, Eugen, और अन्य
  प्रकाशित: (2019)
• Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
  द्वारा: Algarín, Esperanza M, और अन्य
  प्रकाशित: (2020)
• Val-Gly-Val-Ala-Pro-Gly, a repeating peptide in elastin, is chemotactic for fibroblasts and monocytes
  प्रकाशित: (1984)